{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:13:15Z","timestamp":1792411995262,"version":"4.4.0"},"reference-count":81,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Assessment of immune-specific markers is a well-established approach for predicting the response to immune checkpoint inhibitors (ICIs). Promising candidates as ICI predictive biomarkers are the DNA damage response pathway genes. One of those pathways, which are mainly responsible for the repair of DNA damage caused by ultraviolet radiation, is the nucleotide excision repair (NER) pathway. Xeroderma pigmentosum (XP) is a hereditary disease caused by mutations of eight different genes of the NER pathway, or POLH, here together named the nine XP genes. Anecdotal evidence indicated that XP patients with melanoma or other skin tumors responded impressively well to anti-PD-1 ICIs. Hence, we analyzed the expression of the nine XP genes as prognostic and anti-PD-1 ICI predictive biomarkers in melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We assessed mRNA gene expression in the TCGA-SKCM dataset (n = 445) and two pooled clinical melanoma cohorts of anti-PD-1 ICI (n = 75). In TCGA-SKCM, we applied hierarchical clustering on XP genes to reveal clusters, further utilized as XP cluster scores. In addition, out of 18 predefined genes representative of a T cell inflamed tumor microenvironment, the TIS score was calculated. Besides these scores, the XP genes, immune-specific single genes (CD8A, CXCL9, CD274, and CXCL13) and tumor mutational burden (TMB) were cross-correlated. Survival analysis in TCGA-SKCM was conducted for the selected parameters. Lastly, the XP response prediction value was calculated for the two pooled anti-PD-1 cohorts by classification models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In TCGA-SKCM, expression of the XP genes was divided into two clusters, inversely correlated with immune-specific markers. A higher ERCC3 expression was associated with improved survival, particularly in younger patients. The constructed models utilizing XP genes, and the XP cluster scores outperformed the immune-specific gene-based models in predicting response to anti-PD-1 ICI in the pooled clinical cohorts. However, the best prediction was achieved by combining the immune-specific gene CD274 with three XP genes from both clusters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our results suggest pre-therapeutic XP gene expression as a potential marker to improve the prediction of anti-PD-1 response in melanoma.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.810058","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T07:23:33Z","timestamp":1643613813000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The Prognostic and Predictive Role of Xeroderma Pigmentosum Gene Expression in Melanoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Sarah","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Emmert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Wolkenhauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Fuellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Thiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","article-title":"A Decade of Immune-Checkpoint Inhibitors in Cancer Therapy","volume":"11","author":"Robert","year":"2020","journal-title":"Nat Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020221","article-title":"Current Melanoma Treatments: Where Do We Stand","volume":"13","author":"Moreira","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31559-9","article-title":"Melanoma","volume":"392","author":"Schadendorf","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x","article-title":"The Evolving Landscape of Biomarkers for Checkpoint Inhibitor Immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The Next Decade of Immune Checkpoint Therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar3593","article-title":"Pan-Tumor Genomic Biomarkers for PD-1 Checkpoint Blockade-Based Immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-017-0243-4","article-title":"Identifying Baseline Immune-Related Biomarkers to Predict Clinical Outcome of Immunotherapy","volume":"5","author":"Gnjatic","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190","article-title":"IFN-Gamma-Related mRNA Profile Predicts Clinical Response to PD-1 Blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"B10","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-Analysis of Tumor- and T Cell-Intrinsic Mechanisms of Sensitization to Checkpoint Inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and Microenvironment Evolution During Immunotherapy With Nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122010","article-title":"DNA Repair Defects and Implications for Immunotherapy","volume":"128","author":"Bever","year":"2018","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic Correlates of Response to Immune Checkpoint Blockade","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.2425","article-title":"DNA Repair Deficiency and Immunotherapy Response","volume":"36","author":"Mouw","year":"2018","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.7740","article-title":"Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1\/PD-L1 Blockade in Advanced Urothelial Cancers","volume":"36","author":"Teo","year":"2018","journal-title":"J Clin Onc ol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/nature24673","article-title":"Inactivation of DNA Repair Triggers Neoantigen Generation and Impairs Tumour Growth","volume":"552","author":"Germano","year":"2017","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733","article-title":"Mismatch Repair Deficiency Predicts Response of Solid Tumors to PD-1 Blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 Blockade in Tumors With Mismatch-Repair Deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in Cancer Immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101485","article-title":"Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1(-\/-) Mice","volume":"11","author":"Gladbach","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrc.2015.4","article-title":"DNA Repair, Genome Stability and Cancer: A Historical Perspective","volume":"16","author":"Jeggo","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-20-1672","article-title":"Exploiting the Microhomology-Mediated End-Joining Pathway in Cancer Therapy","volume":"80","author":"Patterson-Fortin","year":"2020","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2015.08.006","article-title":"Microhomology-Mediated End Joining: A Back-Up Survival Mechanism or Dedicated Pathway","volume":"40","author":"Sfeir","year":"2015","journal-title":"Trends Biochem Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and Immune-Checkpoint Inhibitor Combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-019-0733-6","article-title":"Base Excision Repair Regulates PD-L1 Expression in Cancer Cells","volume":"38","author":"Permata","year":"2019","journal-title":"Oncogene"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA Double-Strand Break Repair Pathway Regulates PD-L1 Expression in Cancer Cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw199","article-title":"Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer","volume":"109","author":"Parkes","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"B30","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1158\/2326-6066.CIR-18-0277","article-title":"T Cell-Inflamed Versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection","volume":"6","author":"Trujillo","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive Immune Resistance: How Cancer Protects From Immune Attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-17-0226","article-title":"DNA Damage and Repair Biomarkers of Immunotherapy Response","volume":"7","author":"Mouw","year":"2017","journal-title":"Cancer Discov"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26837","article-title":"Dramatic Response to Nivolumab in Xeroderma Pigmentosum Skin Tumor","volume":"65","author":"Chambon","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejca.2017.06.022","article-title":"Rapid Response of Metastatic Cutaneous Squamous Cell Carcinoma to Pembrolizumab in a Patient With Xeroderma Pigmentosum: Case Report and Review of the Literature","volume":"83","author":"Deinlein","year":"2017","journal-title":"Eur J Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.026","article-title":"Regression of Melanoma Metastases and Multiple Non-Melanoma Skin Cancers in Xeroderma Pigmentosum by the PD1-Antibody Pembrolizumab","volume":"77","author":"Hauschild","year":"2017","journal-title":"Eur J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16270","article-title":"Efficacy of Anti-Programmed Cell Death-1 Immunotherapy for Skin Carcinomas and Melanoma Metastases in a Patient With Xeroderma Pigmentosum","volume":"178","author":"Salomon","year":"2018","journal-title":"Br J Dermatol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00028","article-title":"Response to Pembrolizumab in a Patient With Xeroderma Pigmentosum and Advanced Squamous Cell Carcinoma","volume":"3","author":"Steineck","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B38","article-title":"Xeroderma Pigmentosum","volume-title":"GeneReviews\u00ae","author":"Kraemer","year":"2003"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3822","article-title":"Understanding Nucleotide Excision Repair and Its Roles in Cancer and Ageing","volume":"15","author":"Marteijn","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.2010.083022","article-title":"Cancer and Neurologic Degeneration in Xeroderma Pigmentosum: Long Term Follow-Up Characterises the Role of DNA Repair","volume":"48","author":"Bradford","year":"2011","journal-title":"J Med Genet"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100034","article-title":"DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response Beyond Tumor Mutation Burden","volume":"1","author":"Hsiehchen","year":"2020","journal-title":"Cell Rep Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-020-00139-8","article-title":"Mutations in BRCA1 and BRCA2 Differentially Affect the Tumor Microenvironment and Response to Checkpoint Blockade Immunotherapy","volume":"1","author":"Samstein","year":"2021","journal-title":"Nat Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","year":"2015","journal-title":"Cell"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.03.006","article-title":"Prognostic Versus Predictive Value of Biomarkers in Oncology","volume":"44","author":"Oldenhuis","year":"2008","journal-title":"Eur J Cancer"},{"key":"B45","unstructured":"WO2016094377\n            AyersM\n            LobodaA\n            LuncefordJ\n            McclanahanT\n            MurphyE\n            NebozhynM\n          2016"},{"key":"B46","volume-title":"R: A Language and Environment for Statistical Computing Vienna, Austria","year":"2019"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1101\/gr.239244.118","article-title":"Maftools: Efficient and Comprehensive Analysis of Somatic Variants in Cancer","volume":"28","author":"Mayakonda","year":"2018","journal-title":"Genome Res"},{"key":"B48","unstructured":"RevelleW\n          Psych: Procedures for Psychological, Psychometric, and Personality Research2021"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw313","article-title":"Complex Heatmaps Reveal Patterns and Correlations in Multidimensional Genomic Data","volume":"32","author":"Gu","year":"2016","journal-title":"Bioinformatics"},{"key":"B50","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"B51","unstructured":"TherneauTM\n          A Package for Survival Analysis in R2021"},{"key":"B52","unstructured":"KassambaraA\n            KosinskiM\n            BiecekP\n          Survminer: Drawing Survival Curves Using 'Ggplot2'2021"},{"key":"B53","unstructured":"ThieleC\n          Cutpointr: Determine and Evaluate Optimal Cutpoints in Binary Classification Tasks2021"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v098.i11","article-title":"Cutpointr: Improved Estimation and Validation of Optimal Cutpoints in R","volume":"98","author":"Thiele","year":"2021","journal-title":"J Stat Softw"},{"key":"B55","unstructured":"ChenT\n            HeT\n            BenestyM\n            KhotilovichV\n            TangY\n            ChoH\n          Xgboost: Extreme Gradient Boosting2021"},{"key":"B56","unstructured":"KuhnM\n          Caret: Classification and Regression Training2020"},{"key":"B57","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","article-title":"Cell-Of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors From 33 Types of Cancer","volume":"173","author":"Hoadley","year":"2018","journal-title":"Cell"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e0219102","DOI":"10.1371\/journal.pone.0219102","article-title":"Cluster Analysis on High Dimensional RNA-Seq Data With Applications to Cancer Research - An Evaluation Study","volume":"14","author":"Vidman","year":"2019","journal-title":"PloS One"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01233-9","article-title":"Intratumoral Heterogeneity in Cancer Progression and Response to Immunotherapy","volume":"27","author":"Vitale","year":"2021","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a012609","article-title":"Nucleotide Excision Repair in Eukaryotes","volume":"5","author":"Scharer","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.067538","article-title":"The XPA-Binding Domain of ERCC1 Is Required for Nucleotide Excision Repair But Not Other DNA Repair Pathways","volume":"285","author":"Orelli","year":"2010","journal-title":"J Biol Chem"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601894","article-title":"Structural Basis for the Recruitment of ERCC1-XPF to Nucleotide Excision Repair Complexes by XPA","volume":"26","author":"Tsodikov","year":"2007","journal-title":"EMBO J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"9990","DOI":"10.1093\/nar\/gks818","article-title":"DNA Repair Endonuclease ERCC1-XPF as a Novel Therapeutic Target to Overcome Chemoresistance in Cancer Therapy","volume":"40","author":"McNeil","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.05.006","article-title":"Comparison of ERCC1\/XPF Genetic Variation, mRNA and Protein Levels in Women With Advanced Stage Ovarian Cancer Treated With Intraperitoneal Platinum","volume":"126","author":"Deloia","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nature09196","article-title":"Structure and Mechanism of Human DNA Polymerase Eta","volume":"465","author":"Biertumpfel","year":"2010","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01390.x","article-title":"Differential Ultraviolet-B-Induced Immunomodulation in XPA, XPC, and CSB DNA Repair-Deficient Mice","volume":"117","author":"Boonstra","year":"2001","journal-title":"J Invest Dermatol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/j.mrrev.2014.11.004","article-title":"Role of DNA Repair in Host Immune Response and Inflammation","volume":"763","author":"Fontes","year":"2015","journal-title":"Mutat Res Rev Mutat Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.09.003","article-title":"MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells","volume":"22","author":"Altman","year":"2015","journal-title":"Cell Metab"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3390\/biom11050715","article-title":"Circadian Rhythm of NER and ATR Pathways","volume":"11","author":"Kang","year":"2021","journal-title":"Biomolecules"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.567512","article-title":"Prognostic Implications of Novel Ten-Gene Signature in Uveal Melanoma","volume":"10","author":"Luo","year":"2020","journal-title":"Front Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639874","article-title":"A Four-Gene-Based Prognostic Model Predicts Overall Survival in Patients With Cutaneous Melanoma","volume":"11","author":"Tong","year":"2021","journal-title":"Front Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602555","article-title":"Development of an Immune-Related Gene Signature for Prognosis in Melanoma","volume":"10","author":"Zhang","year":"2020","journal-title":"Front Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40425-018-0367-1","article-title":"Pan-Cancer Adaptive Immune Resistance as Defined by the Tumor Inflammation Signature (TIS): Results From The Cancer Genome Atlas (TCGA)","volume":"6","author":"Danaher","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102084","article-title":"Impact of High Tumor Mutational Burden in Solid Tumors and Challenges for Biomarker Application","volume":"89","author":"McNamara","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B75","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1186\/s12967-016-1026-2","article-title":"Impact of Aging on Host Immune Response and Survival in Melanoma: An Analysis of 3 Patient Cohorts","volume":"14","author":"Weiss","year":"2016","journal-title":"J Transl Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030280","article-title":"Observed Survival Interval: A Supplement to TCGA Pan-Cancer Clinical Data Resource","volume":"11","author":"Xiong","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B77","doi-asserted-by":"publisher","first-page":"640","DOI":"10.21037\/atm.2019.10.116","article-title":"Tumor Mutational and Indel Burden: A Systematic Pan-Cancer Evaluation as Prognostic Biomarkers","volume":"7","author":"Wu","year":"2019","journal-title":"Ann Transl Med"},{"key":"B78","doi-asserted-by":"publisher","first-page":"e932052","DOI":"10.12659\/msm.932052","article-title":"Identification of CXCL13 as an Immune-Related Biomarker Associated With Tumorigenesis and Prognosis in Cutaneous Melanoma Patients","volume":"27","author":"Si","year":"2021","journal-title":"Med Sci Monit"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.619003","article-title":"CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1609376113","article-title":"Density of Immunogenic Antigens Does Not Explain the Presence or Absence of the T-Cell-Inflamed Tumor Microenvironment in Melanoma","volume":"113","author":"Spranger","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of Cancer Resistance to Immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.810058\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T07:23:38Z","timestamp":1643613818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.810058\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":81,"alternative-id":["10.3389\/fonc.2022.810058"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.810058","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"article-number":"810058"}}